Antitumor therapy for breast cancer: Focus on tumor-associated macrophages and nanosized drug delivery systems

被引:9
|
作者
Zhan, Cuiping [1 ]
Jin, Ying [2 ]
Xu, Xinzhi [1 ,3 ]
Shao, Jiangbo [1 ]
Jin, Chunxiang [1 ]
机构
[1] Jilin Univ, China Japan Union Hosp, Dept Ultrasound, Changchun, Peoples R China
[2] First Hosp Jilin Univ, Dept Breast Surg, Changchun, Peoples R China
[3] Chongqing Univ, Canc Hosp, Dept Ultrasound, Chongqing, Peoples R China
来源
CANCER MEDICINE | 2023年 / 12卷 / 10期
基金
中国国家自然科学基金;
关键词
breast cancer; macrophages; nanotechnology; target therapy; CHEMOKINE LIGAND 2; MONOCLONAL-ANTIBODY; IMMUNE-RESPONSE; PROTEIN CORONA; CO-DELIVERY; POLARIZATION; NANOPARTICLES; PROGRESSION; CELLS; TARGETS;
D O I
10.1002/cam4.5489
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundIn breast cancer (BC), tumor-associated macrophages (TAMs) are an important component of the tumor microenvironment and are closely related to poor prognosis. A growing number of studies have focused on the role of TAMs in BC progression and therapeutic strategies targeting TAMs. As an emerging treatment, the application of nanosized drug delivery systems (NDDSs) in the treatment of BC by targeting TAMs has attracted much attention. AimsThis review is to summarize the characteristics and treatment strategies targeting TAMs in BC and to clarify the applications of NDDSs targeting TAMs in the treatment of BC by targeting TAMs. Materials & MethodsThe existing results related to characteristics of TAMs in BC, BC treatment strategies by targeting TAMs, and the applications of NDDSs in these strategies are described. Through analyzing these results, the advantages and disadvantages of the treatment strategies using NDDSs are discussed, which could provide advices on designing NDDSs for BC treatment. ResultsTAMs are one of the most prominent noncancer cell types in BC. TAMs not only promote angiogenesis, tumor growth and metastasis but also lead to therapeutic resistance and immunosuppression. Mainly four strategies have been used to target TAMs for BC therapy, which include depleting macrophages, blocking recruitment, reprogramming to attain an anti-tumor phenotype, and increasing phagocytosis. Since NDDSs can efficiently deliver drugs to TAMs with low toxicity, they are promising approaches for targeting TAMs in tumor therapy. NDDSs with various structures can deliver immunotherapeutic agents and nucleic acid therapeutics to TAMs. In addition, NDDSs can realize combination therapies. DiscussionTAMs play a critical role in the progression of BC. An increasing number of strategies have been proposed to regulate TAMs. Compared with free drugs, NDDSs targeting TAMs improve drug concentration, reduce toxicity and realize combination therapies. However, in order to achieve better therapeutic efficacy, there are still some disadvantages that need to be considered in the design of NDDSs. ConclusionTAMs play an important role in the progression of BC, and targeting TAMs is a promising strategy for BC therapy. In particular, NDDSs targeting TAMs have unique advantages and are potential treatments for BC.
引用
收藏
页码:11049 / 11072
页数:24
相关论文
共 50 条
  • [21] Effect of tumor-associated macrophages on the pyroptosis of breast cancer tumor cells
    XuLing Ji
    Xiaoxia Huang
    Chao Li
    Ningning Guan
    Tingting Pan
    Jing Dong
    Lin Li
    Cell Communication and Signaling, 21
  • [22] T cells, NK cells, and tumor-associated macrophages in cancer immunotherapy and the current state of the art of drug delivery systems
    Yang, Ya-long
    Yang, Fei
    Huang, Zhuan-qing
    Li, Yuan-yuan
    Shi, Hao-yuan
    Sun, Qi
    Ma, Yue
    Wang, Yao
    Zhang, Ying
    Yang, Sen
    Zhao, Guan-ren
    Xu, Feng-hua
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [23] Oxygenated lipid signaling in tumor-associated macrophages—focus on colon cancer
    Jennifer K. Colby
    Jonathan Jaoude
    Fuyao Liu
    Imad Shureiqi
    Cancer and Metastasis Reviews, 2018, 37 : 289 - 315
  • [24] Mechanisms of tumor-associated macrophages in breast cancer and treatment strategy
    Jin, Hong
    Meng, Xinyue
    Feng, Jianwei
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [25] Tumor-associated macrophages press the angiogenic switch in breast cancer
    Lin, Elaine Y.
    Pollard, Jeffrey W.
    CANCER RESEARCH, 2007, 67 (11) : 5064 - 5066
  • [26] Tumor-associated macrophages: An important player in breast cancer progression
    Huang, Xinqun
    Cao, Jingsong
    Zu, Xuyu
    THORACIC CANCER, 2022, 13 (03) : 269 - 276
  • [27] Tumor-associated macrophages: Unwitting accomplices in breast cancer malignancy
    Williams C.B.
    Yeh E.S.
    Soloff A.C.
    npj Breast Cancer, 2 (1)
  • [28] TFEB is a master regulator of tumor-associated macrophages in breast cancer
    Li, Yong
    Hodge, Johnie
    Liu, Qing
    Wang, Junfeng
    Wang, Yuzhen
    Evans, Trent D.
    Altomare, Diego
    Yao, Yongzhong
    Murphy, E. Angela
    Razani, Babak
    Fan, Daping
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [29] Multifunctional nanoparticles inhibit tumor and tumor-associated macrophages for triple-negative breast cancer therapy
    Liu, Yan
    Zhang, Dan
    Zhang, Zongquan
    Liang, Xiaoya
    Yang, Xi
    Ding, Nianhui
    Nie, Yu
    Li, Chunhong
    Journal of Colloid and Interface Science, 2024, 657 : 598 - 610
  • [30] Multifunctional nanoparticles inhibit tumor and tumor-associated macrophages for triple-negative breast cancer therapy
    Liu, Yan
    Zhang, Dan
    Zhang, Zongquan
    Liang, Xiaoya
    Yang, Xi
    Ding, Nianhui
    Nie, Yu
    Li, Chunhong
    JOURNAL OF COLLOID AND INTERFACE SCIENCE, 2024, 657 : 598 - 610